Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association
Por:
Garcia-Pavia, P, Gonzalez-Lopez, E, Anderson, LJ, Cappelli, F, Damy, T, Fontana, M, Gonzalez-Costello, J, Jurcut, R, Lairez, O, van der Meer, P, Merlo, M, Perlini, S and Bayes-Genis, A
Publicada:
1 ene 2026
Ahead of Print:
1 oct 2025
Resumen:
This clinical consensus statement, developed by the Heart Failure Association of the European Society of Cardiology, offers a detailed review of the non-specific management of transthyretin amyloid cardiomyopathy (ATTR-CM). This progressive and often fatal condition is increasingly recognized as a major contributor to heart failure. This document provides advice on symptom management and enhancing quality of life, with a focus on volume management, neurohormonal modulation, and tailored use of diuretics and other supportive therapies that address the distinct pathophysiology of ATTR-CM. It also explores advanced treatment modalities such as heart transplantation and mechanical circulatory support, which play crucial roles in managing advanced stages of the disease. Furthermore, it addresses the management of aortic stenosis in the context of ATTR-CM, advising transcatheter aortic valve replacement as the preferred treatment for these patients. The advice provided in this document relies primarily on expert opinion and retrospective studies due to a notable lack of randomized clinical trials, which underscores a critical research gap and the pressing need for evidence-based treatment protocols.
Filiaciones:
Garcia-Pavia, P:
Hosp Univ Puerta Hierro Majadahonda, Dept Cardiol, IDIPHISA, GUARD HEART ERN, Manuel de Falla 2, Madrid 28222, Spain
Inst Salud Carlos III, CIBER Cardiovasc, Madrid, Spain
Ctr Nacl Invest Cardiovasc CNIC, C Melchor Fernandez Almagro 3, Madrid 28029, Spain
Gonzalez-Lopez, E:
Hosp Univ Puerta Hierro Majadahonda, Dept Cardiol, IDIPHISA, GUARD HEART ERN, Manuel de Falla 2, Madrid 28222, Spain
Inst Salud Carlos III, CIBER Cardiovasc, Madrid, Spain
Anderson, LJ:
St George Hosp, Cardiol Clin Acad Grp, London, England
Cappelli, F:
Careggi Univ Hosp, Tuscan Reg Amyloidosis Ctr, Florence, Italy
Damy, T:
APHP CHU Henri Mondor Creteil & Reseau Amylose & F, Referral Ctr Cardiac Amyloidosis, GUARD HEART ERN, Paris, France
APHP CHU Henri Mondor Creteil & Reseau Amylose & F, Dept Cardiol, GUARD HEART ERN, Paris, France
Fontana, M:
Royal Free Hosp, Natl Amyloidosis Ctr, Div Med, UCL, London, England
Gonzalez-Costello, J:
Hosp Univ Bellvitge, Dept Cardiol, Barcelona, Spain
Inst Invest Biomed Bellvitge, Bioheart, Barcelona, Spain
Jurcut, R:
Univ Med & Pharm Carol Davila, Bucharest, Romania
Emergency Inst Cardiovasc Dis Prof dr CC Iliescu, Expert Ctr Rare Cardiovasc Dis, GUARD HEART ERN, Bucharest, Romania
Lairez, O:
Toulouse Univ, HealthAge Univ Hosp Inst, Toulouse, France
van der Meer, P:
Expt Cardiol Univ Med Ctr Groningen, Groningen, Netherlands
Merlo, M:
Azienda Sanit Univ Giuliano Isontina ASUGI, Cardiothoracovasc Dept, GUARD HEART ERN, Trieste, Italy
Univ Trieste, Azienda Sanit Univ Giuliano Isontina ASUGI, Ctr Diag & Treatment Cardiomyopathies, Cardiovasc Dept, Trieste, Italy
Perlini, S:
Univ Pavia, IRCCS Policlin San Matteo Fdn, Emergency Med & Amyloidosis Res & Treatment Ctr, Dept Internal Med, Pavia, Italy
:
Inst Salud Carlos III, CIBER Cardiovasc, Madrid, Spain
Inst Cor Hosp Univ Germans Trias & Pujol, Badalona 08916, Spain
Univ Autonoma Barcelona, Dept Med, Barcelona, Spain
Green Submitted, Bronze
|